- Home
- TSVT vs ENGN Comparison
TSVT vs ENGN Comparison
Compare TSVT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- ENGN
- Stock Information
- Founded
- TSVT 2021
- ENGN 1999
- Country
- TSVT United States
- ENGN Canada
- Employees
- TSVT N/A
- ENGN N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- TSVT Health Care
- ENGN
- Exchange
- TSVT Nasdaq
- ENGN Nasdaq
- Market Cap
- TSVT 258.9M
- ENGN 297.7M
- IPO Year
- TSVT N/A
- ENGN N/A
- Fundamental
- Price
- TSVT $4.95
- ENGN $4.30
- Analyst Decision
- TSVT Buy
- ENGN Buy
- Analyst Count
- TSVT 5
- ENGN 9
- Target Price
- TSVT $7.60
- ENGN $25.22
- AVG Volume (30 Days)
- TSVT 2.5M
- ENGN 28.7K
- Earning Date
- TSVT 03-25-2025
- ENGN 03-10-2025
- Dividend Yield
- TSVT N/A
- ENGN N/A
- EPS Growth
- TSVT N/A
- ENGN N/A
- EPS
- TSVT N/A
- ENGN N/A
- Revenue
- TSVT $37,862,000.00
- ENGN N/A
- Revenue This Year
- TSVT $72.76
- ENGN N/A
- Revenue Next Year
- TSVT $25.59
- ENGN N/A
- P/E Ratio
- TSVT N/A
- ENGN N/A
- Revenue Growth
- TSVT N/A
- ENGN N/A
- 52 Week Low
- TSVT $2.29
- ENGN $4.20
- 52 Week High
- TSVT $5.99
- ENGN $17.54
- Technical
- Relative Strength Index (RSI)
- TSVT 80.79
- ENGN 31.38
- Support Level
- TSVT $2.55
- ENGN $4.20
- Resistance Level
- TSVT $4.97
- ENGN $5.00
- Average True Range (ATR)
- TSVT 0.01
- ENGN 0.51
- MACD
- TSVT -0.00
- ENGN -0.04
- Stochastic Oscillator
- TSVT 60.00
- ENGN 7.14
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.